BRAF alterations in brain tumours: Molecular pathology and therapeutic opportunities

Current Opinion in Neurology

Volumn 27, Issue 6, 2014, Pages 689-696

  Berghoff, Anna Sophie ^a,b   Preusser, Matthias ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Central Nervous System Tumours Unit (CCC CNS)   (Austria)

Author keywords

Brain metastasis; Brain tumours; Gene fusion; Gene mutation; Glioma; v RAF murine sarcoma viral oncogene homologue B1

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; BRAF PROTEIN, HUMAN;

BRAIN METASTASIS; BRAIN TUMOR; CRANIOPHARYNGIOMA; DYSEMBRYOPLASTIC NEUROEPITHELIAL TUMOR; GENE FUSION; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LANGERHANS CELL HISTIOCYTOSIS; MELANOMA; MOLECULAR PATHOLOGY; MUTATION RATE; PAPILLARY CRANIOPHARYNGIOMA; PILOCYTIC ASTROCYTOMA; PLEOMORPHIC XANTHOASTROCYTOMA; POINT MUTATION; REVIEW; CENTRAL NERVOUS SYSTEM; METABOLISM; PATHOLOGY;

BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM; HUMANS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84927788699     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000146     Document Type: Review

References (73)

1. Dhomen N, Marais R. New insight into BRAF mutations in cancer. Curr Opin Genet Dev 2007; 17:31-39.
2. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
3. Ascierto PA, Minor D, Ribas A, et al. Phase II trial (BRAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013; 31:3205-3211.
4. Sleijfer S, Bogaerts J, Siu LL. Designing transformative clinical trials in the cancer genome era. J Clin Oncol 2013; 31:1834-1841.
5. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2. Lancet Oncol 2012; 13:1087-1095.
6. Bautista F, Paci A, Minard-Colin V, et al. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. Pediatr Blood Cancer 2014; 61:1101-1103.
7. Chamberlain MC. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. J Neurooncol 2013; 114:237-240.
8. Skrypek M, Foreman N,Guillaume D, et al. Pilomyxoid astrocytoma treated successfully with vemurafenib. Pediatr Blood Cancer 2014. [Epub ahead of print]
9. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114:97-109.
10. Horbinski C, Hamilton RL, Nikiforov Y, et al. Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas. Acta Neuropathol 2010; 119:641-649.
11. Jones DT, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008; 68:8673-8677.
12. Lin A, Rodriguez FJ, Karajannis MA, et al. BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. J Neuropathol Exp Neurol 2012; 71:66-72.
13. Myung JK, Cho H, Park CK, et al. Analysis of the BRAF(V600E) mutation in central nervous system tumors. Transl Oncol 2012; 5:430-436.
14. Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011; 121:397-405.
15. Capper D, Berghoff AS, Magerle M, et al. Immunohistochemical testing of BRAF V600E status in 1120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 2012; 123:223-233.
16. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954.
17. Pfister S, Janzarik WG, Remke M, et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 2008; 118:1739-1749.
18. Forshew T, Tatevossian RG, Lawson AR, et al. Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol 2009; 218:172-181.
19. Jones DT, Kocialkowski S, Liu L, et al. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 2009; 28:2119-2123.
20. Dias-Santagata D, Lam Q, Vernovsky K, et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One 2011; 6:e17948.
21. Dahiya S, Emnett RJ, Haydon DH, et al. BRAF-V600E mutation in pediatric and adult glioblastoma. Neuro Oncol 2014; 16:318-319.
22. Nobusawa S, Hirato J, Kurihara H, et al. Intratumoral heterogeneity of genomic imbalance in a case of epithelioid glioblastoma with BRAF V600E mutation. Brain Pathol 2014; 24:239-246.
23. Fernandez-Vega I, Quirk J, Norwood FL, et al. Gliomatosis cerebri type 1 with extensive involvement of the spinal cord and BRAF V600E mutation. Pathol Oncol Res 2014; 20:215-220.
24. Nicolaides TP, Li H, Solomon DA, et al. Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res 2011; 17:7595-7604.
25. Korshunov A, Meyer J, Capper D, et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 2009; 118:401-405.
26. Buccoliero AM, Castiglione F, Degl'innocenti DR, et al. Angiocentric glioma: clinical, morphological, immunohistochemical and molecular features in three pediatric cases. Clin Neuropathol 2013; 32:107-113.
27. Donson AM, Kleinschmidt-DeMasters BK, Aisner DL, et al. Pediatric brainstem gangliogliomas show BRAF(V600E) mutation in a high percentage of cases. Brain Pathol 2014; 24:173-183.
28. Dimitriadis E, Alexiou GA, Tsotsou P, et al. BRAF alterations in pediatric low grade gliomas and mixed neuronal-glial tumors. J Neurooncol 2013; 113:353-358.
29. Chappe C, Padovani L, Scavarda D, et al. Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression. Brain Pathol 2013; 23:574-583.
30. Koelsche C, Sahm F, Wohrer A, et al. BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression. Brain Pathol 2014; 24:221-229.
31. Schmidt Y, Kleinschmidt-DeMasters BK, Aisner DL, et al. Anaplastic PXA in adults: case series with clinicopathologic and molecular features. J Neurooncol 2013; 111:59-69.
32. Koelsche C, Wohrer A, Jeibmann A, et al. Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol 2013; 125:891-900.
33. Lindsay AJ, Rush SZ, Fenton LZ. Pediatric posterior fossa ganglioglioma: unique MRI Features and Correlation with BRAF V600E mutation status. J Neurooncol 2014; 118:395-404.
34. Koelsche C, Sahm F, Paulus W, et al. BRAF V600E expression and distribution in desmoplastic infantile astrocytoma/ganglioglioma. Neuropathol Appl Neurobiol 2014; 40:337-344.
35. Sahm F, Capper D, Preusser M, et al. BRAFV600E mutant protein is expressed in cells of variable maturation in langerhans cell histiocytosis. Blood 2012; 120:e28-e34.
36. Brastianos PK, Taylor-Weiner A, Manley PE, et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 2014; 46:161-165.
37. Berghoff AS, Capper D, Preusser M. Lack of BRAF V600E protein expression in primary central nervous system lymphoma. Appl Immunohistochem Mol Morphol 2013; 21:351-353.
38. Badiali M, Gleize V, Paris S, et al. KIAA1549-BRAF fusions and IDH mutations can coexist in diffuse gliomas of adults. Brain Pathol 2012; 22: 841-847.
39. Gessi M, Lambert SR, Lauriola L, et al. Absence of KIAA1549-BRAF fusion in rosette-forming glioneuronal tumors of the fourth ventricle (RGNT). J Neurooncol 2012; 110:21-25.
40. Gessi M, Waha A, Setty P, et al. Analysis of KIAA1549-BRAF fusion status in a case of rosette-forming glioneuronal tumor of the fourth ventricle (RGNT). Neuropathology 2011; 31:654-657.
41. Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, et al. Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol 2013; 37:685-698.
42. Knobbe CB, Reifenberger J, Reifenberger G. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol 2004; 108:467-470.
43. Broniscer A, Tatevossian RG, Sabin ND, et al. Clinical, radiological, histological and molecular characteristics of paediatric epithelioid glioblastoma. Neuropathol Appl Neurobiol 2014; 40:327-336.
44. Tanaka S, Nakada M, Nobusawa S, et al. Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation. Brain Tumor Pathol 2014; 31:172-176.
45. Preusser M, de Ribaupierre S, Wohrer A, et al. Current concepts and management of glioblastoma. Ann Neurol 2011; 70:9-21.
46. Robinson GW, Orr BA, Gajjar A. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer 2014; 14:258.
47. Forst DA, Nahed BV, Loeffler JS, et al. Low-grade gliomas. Oncologist 2014; 19:403-413.
48. Weiler M, Wick W. Molecular predictors of outcome in low-grade glioma. Curr Opin Neurol 2012; 25:767-773.
49. Dahiya S, Haydon DH, Alvarado D, et al. BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathol 2013; 125:901-910.
50. Jeuken JW, Wesseling P. MAPK pathway activation through BRAF gene fusion in pilocytic astrocytomas; a novel oncogenic fusion gene with diagnostic, prognostic, and therapeutic potential. J Pathol 2010; 222:324-328.
51. Jones DT, Gronych J, Lichter P, et al. Mapk pathway activation in pilocytic astrocytoma. Cell Mol Life Sci 2012; 69:1799-1811.
52. Zhang J, Wu G, Miller CP, et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 2013; 45:602-612.
53. Hasselblatt M, Riesmeier B, Lechtape B, et al. BRAF-KIAA1549 fusion transcripts are less frequent in pilocytic astrocytomas diagnosed in adults. Neuropathol Appl Neurobiol 2011; 37:803-806.
54. Horbinski C, Nikiforova MN, Hagenkord JM, et al. Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro Oncol 2012; 14:777-789.
55. Sievert AJ, Lang SS, Boucher KL, et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci U S A 2013; 110:5957-5962.
56. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010; 116:1919-1923.
57. Bubolz AM, Weissinger SE, Stenzinger A, et al. Potential clinical implications of BRAF mutations in histiocytic proliferations. Oncotarget 2014; 5:4060-4070.
58. Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 2013; 121:1495-1500.
59. Heaney ML. Saving orphans: BRAF targeting of histiocytosis. Blood 2013; 121:1487-1488.
60. Larkin SJ, Preda V, Karavitaki N, et al.BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma. Acta Neuropathol 2014; 127:927-929.
61. Capper D, Berghoff AS, von Deimling A, et al. Clinical neuropathology practice news 2-2012: BRAF V600E testing. Clin Neuropathol 2012; 31:64-66.
62. Dummer R, Goldinger SM, Turtschi CP, et al. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 2014; 50: 611-621.
63. Robinson SD, O'Shaughnessy JA, Lance Cowey C, et al. BRAF V600Emutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. Lung Cancer 2014; 85:326-330.
64. Preusser M, Winkler F, Collette L, et al. Trial design on prophylaxis and treatment of brain metastases: lessons learned from the Eortc Brain Metastases Strategic Meeting 2012. Eur J Cancer 2012; 48:3439-3447.
65. Preusser M, Berghoff AS, Schadendorf D, et al. Brain metastasis: opportunity for drug development? Curr Opin Neurol 2012; 25:786-794.
66. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011; 122:11-19.
67. Koperek O, Kornauth C, Capper D, et al. Immunohistochemical detection of the BRAF V600E mutated protein in papillary thyroid carcinoma. Am J Surg Pathol 2012; 36:844-850.
68. Preusser M, Capper D, Berghoff AS, et al. Expression of BRAF V600E mutant protein in epithelial ovarian tumors. Appl Immunohistochem Mol Morphol 2013; 21:159-164.
69. Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol 2013; 37:61-65.
70. Preusser M, Berghoff AS, Capper D, et al. No Evidence for BRAF-V600E mutations in gastroeosophageal tumors: results from a high-throughput analysis of 534 cases using a mutation-specific antibody. Appl Immunohistochem Mol Morphol 2013; 21:426-430.
71. Chi AS, Batchelor TT, Dias-Santagata D, et al. Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol 2012; 110:89-98.
72. Roth JJ, Santi M, Rorke-Adams LB, et al. Diagnostic application of high resolution single nucleotide polymorphism array analysis for children with brain tumors. Cancer Genet 2014; 207:111-123.
73. Janku F, Vibat CR, Kosco K, et al. BRAF V600E mutations in urine and plasma cell-free DNA from patients with erdheim-chester disease. Oncotarget 2014; 5:3607-3610.